The purpose of this study is to evaluate pharmacokinetics and pharmacodynamics of Z-215 (10 mg, 20 mg, 40 mg) , compared with Rabeprazole Sodium (10 mg, 20 mg ) in Healthy Male Subjects. And to evaluate food-effect in Healthy Male Subjects administrated Z-215 20 mg.

Inclusion Criteria:

• Has negative results for H. pylori IgG antibody at screening.
• A body mass index 18.5≦BMI<25.0 kg/m^2 at screening.
• Able to understand the consent of the study and comply with the study. Able to give informed consent in writing before participating in the study.

Exclusion Criteria:

• Has a history of PPI allergy.
• Has a history of drug or food serious allergy.
• Presently has or has a history of diseases that may affect evaluation of the study results such as gastrointestinal, hepatic, renal, respiratory, endocrine, blood, cardiovascular, mental or congenial metabolic disease.
• Has a history of surgery (such as resection of the liver, kidney, or digestive tract) that may affect the pharmacokinetics of the study drug.
• History of previous and current acid-related diseases.
• Received H. pylori eradication treatment within 6 months before screening.
• Has 450msec\